EUR 120.00 For Business Accounts Only

MOSL: HEALTHCARE-IPM growth normalizes to 13.7% YoY in Jul’21, with reduced COVID-19 cases

HEALTHCARE: IPM growth normalizes to 13.7% YoY in Jul’21, with reduced COVID-19 cases

 

• IPM growth was 13.7% YoY in Jul’21 v/s 14.1% YoY in Jun’21.
• Anti-Infectives/Analgesics/Respiratory exhibited a growth of 30%/24.1%/22.8% YoY.
• Respiratory sales were steady YoY in Jul’21 (23.3% YoY growth in Jun’21) as well.
• On a MAT basis, industry growth stood at 12.8% YoY. 

For the quarter-ending Jul’21: Volumes/prices/NP drive IPM growth

• For the quarter-ending Jul’21, YoY growth was 24.3%.
• Prices/new products grew 6.1%/5.4% YoY, boosted by a 12.8% volume increase.

 

Wockhardt, FDC, Indoco Remedies, Ipca, Mankind, and Ajanta outperform

• Among the top 30 corporates, Wockhardt (+45.6% YoY), FDC (+30.3 % YoY), Indoco Remedies (+26.6 YoY), Ipca Laboratories (+25.4% YoY), Mankind Pharma (+23.6% YoY), and Ajanta Pharma (23% YoY) delivered better than IPM growth. With a reduction in the number of COVID-19 cases, Glenmark Pharmaceuticals’ sales declined by 14.4% YoY in Jul’21.
• Ajanta grew on the back of Ophthalmic (~22% of sales), which grew 32% YoY.
• Ipca grew on the back of strong offtake in Pain (~32% of sales), which grew 33% YoY, driven by the Zerodol product franchise.